Senior Scientist, Cancer Biology & Bioinformatics

SUMMARY:

The Senior Scientist, Cancer Biology & Bioinformatics is responsible for providing cancer biology expertise and bioinformatics knowledge to achieve the company's scientific objectives. Key responsibilities include processing and analysis of pre-clinical and clinical correlative studies including next-generation sequencing data, query and analysis of public big-data sets, and scientific oversight of collaborative research activities. The Sr Scientist is expected to work in close collaboration with internal colleagues, external investigators, academic researchers and internal stakeholders, and participates in writing, reviewing and presenting abstracts, publications and other scientific documents. A successful candidate should possess skills necessary to understand basic molecular biology experimental studies.

RESPONSIBILITIES:

• Informatics processing of bulk RNA sequencing, and genome/exome/target panel DNA sequencing, including interpretation of results of analyses.
• Plan, implement and oversee scientific aspects of collaborative projects focused on mechanistic, pre-clinical and biomarker studies relevant to Karyopharm research and development objectives.
• Provide scientific, technical and bioinformatics support to investigators, collaborators and internal stakeholders.
• Present data at key scientific meetings/conferences regarding company's products and research
• Develop in-depth knowledge of therapeutic areas, current medical practice and industry regulations in order to ensure best practice across all activities
• Design and analyze experiments using cancer disease model for novel compound testing and mechanism of action studies with academic collaborators and CROs.

QUALIFICATIONS:

• PhD degree in bioinformatics, cell biology, molecular biology or a related discipline
• 5+ years of working experience in a pharma, biotech or academic setting focused on oncology
• Deep understanding of cancer biology and genetics.
• Experience with processing, analysis and interpretation/presentation of next-generation sequencing data.
• Proficiency in Linux cluster computer environment.
• Experience in working with public cancer genomics databases such as TCGA, ICGC, COSMIC, cBioPortal.
• Experience and knowledge of standard cellular and molecular biology techniques (Cell culture, ELISA, Cell-based assays, Immunofluorescence, Western blotting, Microscopy, RNA/DNA isolation, qPCR)
• Experience related to cancer immunology is desired
• Excellent written and oral communication skills
• Requires strong attention to detail in composing and proofing materials, establishing priorities, scheduling and meeting deadlines
• Must be able to work in a fast-paced environment with demonstrated ability to juggle multiple competing tasks and demands
• Ability to work successfully within a cross-functional team and in a matrixed environment where influence without authority is critical
• Ability to interact with investigators, vendors, and internal colleagues
• Ability to complete tasks to deadlines and resolve/elevate problems in a timely manner

Karyopharm Therapeutics Inc. (NASDAQ: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of first-in-class drugs directed against nuclear export for the treatment of cancer and other diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's lead compound, XPOVIO® (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade® (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. NEXPOVIO® (selinexor) has also been granted conditional marketing authorization in combination with dexamethasone for adult patients with heavily pretreated multiple myeloma by the European Commission. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. For more information, please visit www.karyopharm.com.

Karyopharm Therapeutics Inc. (the "Company") is an equal opportunity employer. All qualified applicants will be considered without regard to age, race, color, sex, religion/creed, national origin, marital status, ancestry, citizenship, military, reservist or veteran status, pregnancy, sexual orientation or preference, gender identity, gender expression, physical or mental disability, genetic predisposition or carrier status, or any other category protected under applicable federal, state or local law. Consistent with its obligations under applicable law, the Company will make reasonable accommodations for qualified individuals with disabilities. If you require an accommodation in the application process, please contact a member of the Company's Human Resources department.